Clinical trial
Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients…
NCT03709901 · VIVEX Biologics, Inc., Industry · Unknown status
Key facts
| NCT number | NCT03709901 |
|---|---|
| Title | Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain |
| Official title | Viable Allograft Supplemented Disc Regeneration in the Treatment of Patients With Low Back Pain With or Without Intervertebral Disc Herniation - VAST Trial |
| Acronym | VAST |
| Lead sponsor | VIVEX Biologics, Inc., Industry |
| Status | Unknown status |
| Study type | Interventional |
| Conditions | Degenerative Disc Disease |
| Intervention type | Other |
| Interventions | Active Allograft, Placebo |
| Enrollment | 218 |
| Start date | Aug 22, 2017 |
| Primary completion | Jan 31, 2022 |
| Completion | Jan 31, 2022 |
| First posted | Oct 17, 2018 |
| Last update posted | Jul 7, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: